Zobrazeno 1 - 10
of 239
pro vyhledávání: ''
Autor:
Yi Li, Guojun Yue, Hui Dong, Yunliang Cao, Fang Chen, Qiaoyuan Wu, Qing Luo, Yudi Dong, Ni Jiang
Publikováno v:
Anti-Cancer Drugs
Since the treatment of lung squamous cell carcinoma (SCC) was limited due to a lack of appropriate biomarkers and novel target agents. Immune checkpoint inhibitors can offer an effective treatment for patients with advanced non-small cell lung cancer
Publikováno v:
Anti-Cancer Drugs
OBJECTIVE A retrospective study was conducted to analyze which translational therapy, palliative chemotherapy and surgery is the best treatment for locally advanced and advanced pancreatic cancer, and to screen out the dominant population for the bes
Publikováno v:
Anti-Cancer Drugs. 33:e534-e540
We aimed to assess the prognostic and predictive significance of pretreatment Prognostic Nutritional Index (PNI) in extensive-stage small-cell lung cancer (ES-SCLC) patients treated with first-line chemotherapy. We designed this study to evaluate the
Publikováno v:
Anti-Cancer Drugs
Programmed cell death protein 1 (PD-1) inhibitors have demonstrated promising activity among patients with advanced soft tissue sarcomas (STS) in phase II trials. The purpose of this study was to assess the efficacy and safety of toripalimab (a novel
Autor:
Kazuhiko Nakagawa, Seiichiro Mitani, Shinichiro Suzuki, Takashi Kurosaki, Yasumasa Nishimura, Hidetoshi Hayashi, Soichi Fumita, Naoki Otsuki, Kazuki Ishikawa, Takeshi Yoshida, Katsumi Doi, Hiroaki Kanemura, Koji Haratani, Kaoru Tanaka, Mutsukazu Kitano, Tsutomu Iwasa
Publikováno v:
Anti-Cancer Drugs
Immunotherapy has been shown to prolong survival in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in front-line use; however, subsequent systemic therapy has not been optimized. This study aimed to evaluate the safety a
Autor:
Ryoichi Imamura, Atsunari Kawashima, Motohide Uemura, Yoko Koh, Akira Nagahara, Takeshi Ujike, Kazutoshi Fujita, Yasushi Miyagawa, Norio Nonomura, Hiroshi Kiuchi
Publikováno v:
Anti-Cancer Drugs
We report the failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer. A 76-year-old man was admitted to our hospital for evaluation of an elevated serum p
Publikováno v:
Anti-Cancer Drugs. 31:737-741
Repurposing commonly prescribed noncancer medications for use in oncology has substantial advantages over de-novo development of anticancer drugs. Calcium signalling has been implicated in many of the hallmarks of cancer. Previous in-vitro and in-viv
Autor:
Hideki Marushima, Hiroyuki Kimura, Haruhiko Nakamura, Hisashi Saji, Naoki Furuya, Hiroki Sakai, Kojima Koji, Tomoyuki Miyazawa
Publikováno v:
Anti-Cancer Drugs
The relatively low toxicity profile of nab-paclitaxel plus carboplatin and its feasibility as an adjuvant administration was reported previously. This study aimed to evaluate the survival efficacy for completely resected patients with stage IB, II, a
Publikováno v:
Anti-cancer drugs. 32(10)
Cetuximab is an IgG1 chimeric mAb against epidermal growth factor receptor, which can be used for chemotherapy failure or tolerance in patients with epidermal growth factor receptor expressed RAS wild-type metastatic colorectal cancer. We report on a
Autor:
Kosuke Hamai, Shintaro Miyamoto, Nobuhisa Ishikawa, Hiroyasu Shoda, Yasushi Horimasu, Yoshikazu Awaya, Takeshi Masuda, Soichi Kitaguchi, Masahiro Yamasaki, Ayako Nishida, Shun Takao, Noboru Hattori, Tomohiro Kondo, Seika Tamamoto, Junko Furutama, Kazunori Fujitaka
Publikováno v:
Anti-Cancer Drugs.
Platinum doublet is the standard chemotherapy regimen for unresectable nonsmall-cell lung cancer (NSCLC) without a driver mutation. However, for squamous cell lung cancer, the most effective cytotoxic regimen is not yet established. Combination thera